Medication info

Verasil Prefilled Syringe Kit

Prescription medication
Ingredient · strength
Human Fibrinogen›80mg / 1 prefilled syringeHuman Thrombin›Strength being verified
Manufacturer / importer
Johnson & Johnson Medical Korea Co. Ltd.
Appearance
A colorless or pale yellow frozen solution contained in a colorless transparent prefilled syringe, which, upon thawing, becomes a colorless or pale yellow liquid.
Packaging
1 kit/box [kit 2mL (1 fibrinogen prefilled syringe 1mL + 1 thrombin prefilled syringe 1mL)], 1 kit/box [kit 4mL (1 fibrinogen prefilled syringe 2mL + 1 thrombin prefilled syringe 2mL)], 1 kit/box [kit 6mL (1 fibrinogen prefilled syringe 3mL + 1 thrombin prefilled syringe 3mL)], 1 kit/box [kit 10mL (1 fibrinogen prefilled syringe 5mL + 1 thrombin prefilled syringe 5mL)]
Approval status
Active

MFDS item code 202203677 · Approved 2022.09.27 · Insurance code 650800511,650800512

Summary

Main use
Assistance with suturing in vascular surgery; improved hemostasis during surgery
Who uses it
Adults · Children
Adult dosage
The amount and frequency of application of this medicine should always be based on the patient's clinical needs. The amount used depends on the type of surgery, the size of the area of application, the method of application, and the number of applications. The attending physician should determine the amount of this medicine for each individual patient. In clinical trials, 0.3mL to 12mL was generally used in adult patients. Larger amounts may be required for other surgeries. The initial amount of the product applied to the selected anatomical site or target surface should be sufficient to completely cover the area of application. Application may be repeated as needed. The surface area that can be covered by each package size of this medicine is shown in Table 1. Table 1. Surface area that can be covered Package size — Surface area that can be covered (cm2) Applied by the drip or spray method (1 mm thick) 2 ml — 16 - 22 4 ml — 32 - 44 6 ml — 48 - 66 10 ml — 80 - 110 Apply this medicine to the wound surface (epilesional use).
Children's dosage
Patients 2 years of age and older: Up to 12mL was used. Patients under 2 years of age: Up to 6mL was used.

Ingredients

Importer
Johnson & Johnson Medical Korea Co. Ltd.

Efficacy & effects

Assistance with suturing in vascular surgery; improved hemostasis during surgery

View approved original text

This drug helps effectively stop bleeding in adult and pediatric patients during surgery when controlling bleeding through standard surgical techniques (suturing, ligation, or cautery, etc.) is difficult. It also assists in suturing during vascular surgery to reduce bleeding and enhance the safety of the procedure. This helps prevent complications due to bleeding and improves hemostasis to support patient recovery.

Dosage and Administration

Adult dosage

The amount and frequency of application of this medicine should always be based on the patient's clinical needs. The amount used depends on the type of surgery, the size of the area of application, the method of application, and the number of applications. The attending physician should determine the amount of this medicine for each individual patient. In clinical trials, 0.3mL to 12mL was generally used in adult patients. Larger amounts may be required for other surgeries. The initial amount of the product applied to the selected anatomical site or target surface should be sufficient to completely cover the area of application. Application may be repeated as needed. The surface area that can be covered by each package size of this medicine is shown in Table 1. Table 1. Surface area that can be covered Package size — Surface area that can be covered (cm2) Applied by the drip or spray method (1 mm thick) 2 ml — 16 - 22 4 ml — 32 - 44 6 ml — 48 - 66 10 ml — 80 - 110 Apply this medicine to the wound surface (epilesional use).

Children's dosage

Patients 2 years of age and older: Up to 12mL was used. Patients under 2 years of age: Up to 6mL was used.

Precautions

This drug is made from human plasma and may contain infectious materials or viruses. Currently, there is no scientific method to completely eliminate this risk, so patients with hemophilia or those who are immune-compromised are recommended to receive vaccinations such as the Hepatitis A vaccine. The risk of infection should be regularly monitored by a physician while using this drug. This drug should only be used on wound surfaces and must never be administered intravenously. If injected intravascularly, serious complications such as thrombosis or embolism, which can be life-threatening, may occur. Patients with allergies or hypersensitivity to the components in this drug should not use it. Additionally, this drug should not be used for severe arterial bleeding. Rarely, allergic reactions such as hives, itching, difficulty breathing, or hypotension may occur while using this drug, and in severe cases, anaphylactic shock may develop. Those who use this drug repeatedly or are sensitive to its components may have a higher risk of such reactions. Care should be taken to avoid dangerous conditions such as thrombosis or disseminated intravascular coagulation (DIC) if mistakenly injected intravenously. Women who are pregnant or nursing should only use this drug if absolutely necessary because its safety has not been sufficiently established. This drug should not be mixed with other medications, and contact with antiseptics containing alcohol or iodine may lead to drug degradation, so caution is required. The wound area must be kept clean and dry before use, and applying the drug too thickly may reduce its effectiveness or impede wound healing. When storing, it must be kept frozen (-18 degrees Celsius or below) and after thawing, should not be refrozen and must be used within the specified period. It is important to protect areas of the body not being treated from contact with the drug when using this drug.

Side effects

Hypersensitivity reactions, allergic reactions, angioedema, burning sensation at the application site, stinging at the application site, bronchospasm, chills, flushing, generalized urticaria, headache, rash, hypotension, drowsiness, nausea, anxiety, tachycardia, chest tightness, numbness, vomiting, wheezing, anaphylaxis, thromboembolism, disseminated intravascular coagulation, abdominal abscess, soft tissue infection, liver abscess, peritonitis, postoperative wound infection, wound infection, incision site infection, post-procedural infection, plasmacytoma, anemia, hemorrhagic anemia, leukocytosis, leukopenia, hyperglycemia, hyperkalemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypoalbuminemia, anxiety, insomnia, headache, drowsiness, conjunctival irritation, atrial fibrillation, ventricular tachycardia, deep vein thrombosis, hypertension, hypotension, pulmonary embolism, respiratory distress, hypoxemia, pleural effusion, pleuritis, pulmonary edema, various dry rales, wheezing, nausea, constipation, abdominal distension, intestinal obstruction, retroperitoneal hematoma, vomiting, pruritus, petechiae, erythema, back pain, limb pain, bladder spasms, dysuria, urinary retention, chills, high fever, peripheral edema, pain, fever, hematoma at the vascular puncture site, alanine aminotransferase increase, aspartate aminotransferase increase, blood bilirubin increase, blood glucose increase, international normalized ratio increase, prothrombin time prolongation, aminotransferase increase, decreased urine output, procedure-related pain, abdominal wound dehiscence, post-procedural bile leakage, bruise, incision site erythema, incision site pain, post-procedural bleeding, procedure-related hypotension, vascular graft complications, vascular graft thrombosis, wound secretion

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to avoid contact with air and must be kept at frozen temperatures below -18 degrees Celsius to maintain its freshness and efficacy.

Appearance and packaging

Appearance

A colorless or pale yellow frozen solution contained in a colorless transparent prefilled syringe, which, upon thawing, becomes a colorless or pale yellow liquid.

Package unit

1 kit/box [kit 2mL (1 fibrinogen prefilled syringe 1mL + 1 thrombin prefilled syringe 1mL)], 1 kit/box [kit 4mL (1 fibrinogen prefilled syringe 2mL + 1 thrombin prefilled syringe 2mL)], 1 kit/box [kit 6mL (1 fibrinogen prefilled syringe 3mL + 1 thrombin prefilled syringe 3mL)], 1 kit/box [kit 10mL (1 fibrinogen prefilled syringe 5mL + 1 thrombin prefilled syringe 5mL)]

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.